Status:

COMPLETED

CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib

Lead Sponsor:

pharmaand GmbH

Conditions:

Metastatic Castration-Resistant Prostate Cancer

Ovarian Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This protocol is designed to provide participants currently benefiting from rucaparib treatment in a Clovis-sponsored clinical study with continued access to treatment for as long as they continue to ...

Detailed Description

Participants enrolled in this study are required to have completed an End-of-Treatment (EOT) Visit with associated assessments as specified in the Clovis-sponsored parent study (NCT01891344; NCT019682...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Currently enrolled in a Clovis-sponsored study of rucaparib that is being closed
  • Either: (a) Is currently tolerating a rucaparib treatment regimen in the parent study with evidence of clinical benefit, as assessed by the investigator, or (b) Has discontinued treatment and is being followed for collection of LTFU data in the parent study
  • Demonstrated compliance with the parent study requirements, as assessed by the investigator, and participant is able and willing to comply with the necessary study visits and assessments as part of the rollover study
  • Provided written informed consent prior to enrolling in this rollover study
  • Exclusion Criteria (applicable only to participants considered for continuation of rucaparib treatment):
  • Participant has been permanently discontinued from study treatment in the parent study for any reason
  • Pregnant or breastfeeding female patients
  • Presence of any other condition that may, in the opinion of the investigator, make the participant inappropriate for continuation of rucaparib treatment.

Exclusion

    Key Trial Info

    Start Date :

    March 22 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    March 8 2023

    Estimated Enrollment :

    34 Patients enrolled

    Trial Details

    Trial ID

    NCT04676334

    Start Date

    March 22 2021

    End Date

    March 8 2023

    Last Update

    May 7 2024

    Active Locations (25)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 7 (25 locations)

    1

    London Regional Cancer Centre

    London, Ontario, Canada

    2

    Institut De Recherche De L'Hospital D'Ottawa

    Ottawa, Ontario, Canada

    3

    Princess Margaret Hospital - Toronto

    Toronto, Ontario, Canada

    4

    Centre Hospitalier de L'Universite de Montreal (CHUM)

    Montreal, Quebec, Canada